

Central Lancashire Online Knowledge (CLoK)

Title	Antiparasitic activity of bromotyrosine alkaloids and new analogues isolated from the Fijian marine Sponge <i>Aplysinella rhax</i>
Type	Article
URL	https://clock.uclan.ac.uk/34161/
DOI	https://doi.org/10.1002/cbdv.202000335
Date	2020
Citation	Oluwabusola, Emmanuel Tope, Tabudravu, Jioji, Al Maqbali, Khalid, Annang, Frederick, Pérez-Moreno, Guiomar, Reyes, Fernando and Jaspars, Marcel (2020) Antiparasitic activity of bromotyrosine alkaloids and new analogues isolated from the Fijian marine Sponge <i>Aplysinella rhax</i> . <i>Chemistry & Biodiversity</i> , 17 (10). e2000335. ISSN 1612-1872
Creators	Oluwabusola, Emmanuel Tope, Tabudravu, Jioji, Al Maqbali, Khalid, Annang, Frederick, Pérez-Moreno, Guiomar, Reyes, Fernando and Jaspars, Marcel

It is advisable to refer to the publisher's version if you intend to cite from the work.
<https://doi.org/10.1002/cbdv.202000335>

For information about Research at UCLan please go to <http://www.uclan.ac.uk/research/>

All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the <http://clock.uclan.ac.uk/policies/>

Antiparasitic Activity of Bromotyrosine Alkaloids and New Analogues Isolated from the Fijian Marine Sponge *Aplysinella rhax*

Emmanuel T. Oluwabusola,^{*a} Jioji N. Tabudravu,^{*b} Khalid S. Al Maqbali,^b Frederick Annang,^c Guiomar Pérez-Moreno,^d Fernando Reyes,^c and Marcel Jaspars^a

^a Marine Biodiscovery Centre, Department of Chemistry, University of Aberdeen, AB24 3UE, Old Aberdeen, UK, e-mail: r01eto16@abdn.ac.uk

^b School of Forensic and Applied Sciences, Faculty of Science and Technology, University of Central Lancashire, Preston, PR1 2HE, UK, e-mail: jtabudravu@uclan.ac.uk

^c Fundación MEDINA, Parque Tecnológico de Ciencias de la Salud, Avenida del Conocimiento, 34.18016-Armilla, Granada, Spain

^d Instituto de Parasitología y Biomedicina 'López-Neyra', Consejo Superior de Investigaciones Científicas, Parque Tecnológico de Ciencias de la Salud, Avenida del Conocimiento, 17, 18016-Armilla, Granada, Spain

© 2020 The Authors. Chemistry & Biodiversity Published by Wiley-VHCA AG. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Ten bromotyrosine alkaloids were isolated and characterised from the marine sponge *Aplysinella rhax* (de Laubenfels 1954) collected from the Fiji Islands, which included one new bromotyrosine analogue, psammaplin P and two other analogues, psammaplin O and 3-bromo-2-hydroxy-5-(methoxycarbonyl)benzoic acid, which have not been previously reported from natural sources. HR-ESI-MS, 1D and 2D NMR spectroscopic methods were used in the elucidation of the compounds. Bisaprasin, a biphenylic dimer of psammaplin A, showed moderate activity with IC_{50} at 19 ± 5 and 29 ± 6 μ M against *Trypanozoma cruzi* Tulahuen C4, and the lethal human malaria species *Plasmodium falciparum* clone 3D7, respectively, while psammaplins A and D exhibited low activity against both parasites. This is the first report of the antimalarial and antitrypanosomal activity of the psammaplin-type compounds. Additionally, the biosynthesis hypotheses of three natural products were proposed.

Keywords: psammaplin, Chagas disease, bromotyrosine, malaria, sponge.

Introduction

The scourge of tropical diseases caused by kinetoplastid parasites, *Plasmodium falciparum* and *Trypanosoma cruzi* has negatively impacted the health of a substantial group of the world population living mostly in the developing world and has led to the death of millions of people.^[1] Chagas disease otherwise refers to as America Trypanosomiasis, is a chronic parasitic infection caused by *Trypanosoma Cruzi* discovered by the Brazilian physician, Carlos Chagas, in 1909.^[2] Chagas disease is primarily confined to Latin America

and southern parts of North America, but has spread to many developed countries owing to migration.^[2,3] People infected with Chagas disease are usually asymptomatic, and one-third of them later develop a chronic form of the disease which can manifest as cardiac disease and is the leading cause of morbidity and mortality in affected countries.^[2,4] The recent infection cases reported for malaria and Chagas diseases are estimated to be 228 million and 6–7 million, respectively.^[5,6] To make the matter worse, the *Plasmodium* parasite that causes malaria has developed resistance against the current therapeutic drugs (Artesunate) and Artemisinin-based combination therapies (ACT), which first emerged on Cambodia–Thailand border,^[7,8] despite the huge resources channelled into vaccine development, no

Supporting information for this article is available on the WWW under <https://doi.org/10.1002/cbdv.202000335>

vaccine seems to be in view.^[9] There is a high demand for an affordable and safe drug to help reduce the scourge of infection in the affected countries.^[10,11] Enormous progress is being made to eradicate these diseases a significant effort of which is concentrated on finding less toxic therapeutic agents against Chagas disease.^[12]

Marine sponges (phylum Porifera) are among the oldest multicellular animals in the world.^[13] They are highly diverse and capable of biosynthesising a greater variety of natural bioactive natural products than other invertebrate phyla.^[14] Investigation of compounds isolated from taxa in the class Demospongiae, order Verongida, confirmed the presence of a high number of nitrogen-containing secondary metabolites,^[15] and in particular, a diverse array of brominated tyrosine derivatives.^[16,17] Marine sponges have contributed immensely to natural product discovery and were responsible for nearly 30% of all of the secondary metabolites produced till date.^[18] Compounds isolated from the Verongida showed a wide range of bioactivities such as antifoulant,^[19–22] anticancer,^[23–27] antimicrobial,^[28–31] antifungal,^[32,33] and enzymatic activities^[34–37] with IC₅₀ values at low micromolar levels. Aeroplysinin I, an optically active bioactive small molecule, was the first brominated metabolite isolated from a sponge *Aplysina aerophoba* (family Aplysinidae) collected from the Mediterranean Sea,^[38] and reported to possess moderate inhibition against *Plasmodium*

falciparum and *Trypanosoma cruzi*.^[39] Other marine-derived bromotyrosine alkaloids such as psammaplysinas F and H, and 11-hydroxyaerotherionin have shown promising antimalarial activities.^[40–43]

In our search for new metabolites from marine sources against these diseases, the methanolic extract of the sponge *Aplysinella rhax*, collected from the Fiji Islands was subjected to sequential fractionation and purification, indicating that 3 of the 10 compounds have now been isolated for the first time from natural sources. Herein, we report the structure elucidation of the three marine-derived compounds and antiparasitic activities of most of the compounds isolated (1–7, 9–10).

Results and Discussion

The marine sponge extract was partitioned between water and dichloromethane (50% v/v) using a modified Kupchan method^[44] previously described^[45,46] and further fractionated using reversed-phase solid-phase extraction (SPE). The resulting fractions were purified on reversed-phase HPLC to yield psammaplysin A (1),^[16,47–50] B–D (2–4),^[16,49] O (5) and P (6), 3-bromo-2-hydroxy-5-(methoxycarbonyl)benzoic acid (7), 2-(3-bromo-4-hydroxyphenyl)acetonitrile (8),^[16,50] 3-bromo-4-hydroxybenzoic acid (9),^[51] and bisaprasin (10) (Figure 1).^[47–50] All known compounds were identified by




Figure 1. Structures of compounds 1–10.

comparison of experimental NMR and HR-ESI-MS data with those published.

Compound **5** was obtained as yellowish oil. High-resolution electrospray ionisation mass spectrometry HR-ESI-TOF-MS revealed a protonated 1:1 isotopic cluster indicating the presence of one bromine atom at m/z 380.9746/382.9725 $[M+H]^+$ in accordance with the molecular formula of $C_{11}H_{14}BrN_2O_6S$, requiring 6 degrees of unsaturation (see *Figure S21*).

The 1H , ^{13}C and HSQC data of **5** (*Table 1*) showed the presence of five quaternary carbons, three methylene and three methine groups. Detailed analysis of 1H chemical shifts, coupling constants, and COSY data suggested the presence of a 1,3,4-trisubstituted aromatic ring with H-13 (δ_H 7.07) coupling to both H-12 (δ_H 6.76, $J=8.4$), and H-9 (δ_H 7.36, $J=2.0$). The position of the methylene singlet H-7 was deduced from HMBCs to C-9 (δ_C 134.3), and C-13 (δ_C 130.2) in the aromatic ring, C-6 (δ_C 151.3, oxime), and C-5 (δ_C

165.4, carboxamide) units. The unusual ^{13}C downfield chemical shift for the CH_2 group at C-2 (δ_C 50.8 ppm) suggested that it was attached to the resonance stabilised electron-withdrawing sulfonate group at this position (*Figure 2*). Similar ^{13}C chemical shifts can be found for psammaplin C^[16] that contains the SO_2NH_2 group at C-2 instead of SO_2OH as in **5**. All 1H , HSQC, COSY, and HMBC (*Figures 2* and *S22–27*, *Table 1* and *S63*) data were consistent with published data for psammaplin-type molecules,^[16] suggesting that the structure of **5** was correct. Even though this article represents the first report of compound **5** from marine sources, it has been previously described as a semi-synthetic product obtained through MCPBA-mediated oxidation of psammaplin I.^[52] The NMR data of **5** were consistent with those reported for the semisynthetic version providing further evidence for the structure of **5**.

Table 1. 1H - and ^{13}C -NMR data for compounds **5**, **6** and **7** in CD_3OD . δ in ppm, J in Hz.

Position	5 $\delta_C^{[a]}$	$\delta_H^{[b]}$	6 $\delta_C^{[a]}$	$\delta_H^{[b]}$	7 $\delta_C^{[a]}$	$\delta_H^{[b]}$
1					171.4, C	
2	50.8, CH_2	2.98 (t, $J=6.6$)	37.4, CH_2	2.86 (t, $J=6.6$)	114.4, C	
3	35.8, CH_2	3.67 (t, $J=6.6$)	39.2, CH_2	3.57 (t, $J=6.6$)	162.3, C	
4					110.2, C	
5	165.4, C		165.6, C		138.4, CH	8.30 (d, $J=2.1$)
6	151.3, C		152.8, C		121.2, C	
7	28.2, CH_2	3.79 (s)	28.3, CH_2	3.81 (s)	131.8, CH	8.50 (d, $J=2.1$)
8	130.3, C		130.2, C		165.2, C	
9	134.3, CH	7.36 (d, $J=2.0$)	134.2, CH	7.38 (d, $J=2.0$)	51.1, CH_3	3.89 (s)
10	109.6, C		110.3, C			
11	152.4, C		153.5, C			
12	116.7, CH	6.76 (d, $J=8.4$)	116.8, CH	6.79 (d, $J=8.4$)		
13	130.2, CH	7.07 (dd, $J=8.4, 2.0$)	130.2, CH	7.09 (dd, $J=8.4, 2.0$)		
2'			38.2, CH_2	2.86 (t, $J=6.6$)		
3'			39.5, CH_2	3.57 (t, $J=6.6$)		
5'			158.9, C			
6'			161.6, C			
7'			53.3, CH_3	3.88 (s)		

^[a] Measured at 150 MHz for ^{13}C -NMR. ^[b] Measured at 600 MHz for 1H -NMR in CD_3OD .




Figure 2. Selected COSY and HMBC data for compounds **5**, **6** and **7**.

The molecular mass of compound **6** was determined by high-resolution ESI-TOF-MS as 494.0065 [M + H]⁺ corresponding to a molecular formula of C₁₆H₂₀BrN₃O₆S₂, requiring 8 degrees of unsaturation (Figures S28–S29). Analysis of 1D and 2D NMR data (Tables 1 and S63, Figures 1 and S30–35) suggested that the general backbone for **6** was essentially that of psammoplin F^[50] with the exception of the presence of an *O*-methyl group in **6** to form an ester. The presence of protonated and sodium adducts at *m/z* 274.9545 (M + H)⁺ and 296.9364 (M + Na)⁺ in the ESI-TOF spectrum of **7** suggested a molecular formula of C₉H₇BrO₅, requiring **6** degrees of unsaturation (Figures S36–S37). It also displayed the same isotopic pattern shown by **5** indicating the presence of one bromine atom in the structure of **7**.

Analysis of ¹³C and HSQC data (Table 1, Figures S39) showed the presence of six quaternary carbons, one methoxy group, while ¹H-NMR and COSY data (Figures S38 and S40) suggested the presence of a 1,2,3,5-tetrasubstituted aromatic spin system. The 2.1 coupling of H-5 to H-7 suggested their *meta* relationship. HMBCs between H-5 (δ_H 8.30) and H-7 (δ_H 8.50) to C-6 and C-8, and between H-9 (δ_H 3.89) and C-8 confirmed the placement of the methyl ester functionality at C-8 (Figures 2 and S41, Tables 1 and S63). There is HMBC strong correlation between both H-5 and H-7 to the oxygenated carbon C-3 (δ_C 162.3) and from H-7 to C-1 (δ_C 171.4). The resonance signal at δ_C 110.2 assigned to C-4 was suggestive of the shielding effect of the bromine atom^[53] consistent with the brominated carbon C-10 in both **5** and **6** (see Table 1). The structure of **7** was determined by assigning the hydroxy group and carboxylic acid substituent to C-3 and C-1, respectively, based on HMBC and chemical shift. Interestingly, compound **7** was previously synthesised,^[54,55] and there was only ¹H-NMR information available in the literature^[55] and was consistent with the data obtained for **7**.


The configuration of the oxime groups is assigned as (*E*) for compounds **5** and **6** based on ¹³C and ¹H data. This is in accordance with the model carried out by Arabshahi and Schmitz^[47] where ¹³C chemical shifts of the benzylic carbons varied diagnostically with geometry. The modified bromotyrosine and cysteine are the basic structural scaffold of psammoplin A and other derivatives isolated from the sponge extract and the biosynthetic pathway of psammoplin-type compounds have been extensively studied.^[16,50]

As predicted by Pina and co-workers,^[16] the logical precursor for the biosynthetic origin of **8** and **9** was the modification of tyrosine through condensation,

decarboxylation process and subsequent oxidation of 3-bromo-4-hydroxybenzaldehyde.^[50] Based on this prediction, the biosynthetic hypothesis of **7** was proposed to be through further methylation of **9**, followed by carboxylation process (Scheme 1). Psammoplin P (**6**) was undoubtedly an esterified derivative of psammoplin F, the biosynthetic pathway of which was proposed to have originated from the formation of cysteine^[16] intermediate through oxidation of a dimerised cysteine modification possibly catalysed by cytochrome P450 enzymes in union with bromotyrosine units via a condensation reaction,^[50] followed by methylation of the carboxylic acid functionality (Scheme 1).

On the other hand, compound **5** (Scheme 1) can be rationalised by the reaction of rearranged cysteine as proposed by Jimenez and Crews^[50] with bromotyrosine to form the bromotyrosine-cysteine unit containing a reactive thiol nucleophile (–SH) that undergoes oxidation via reactive oxygen species (ROS) and reactive nitrogen species (RNS) to form sulphenic acid (–SOH) as an intermediate reacting further to form sulfinic acid (–SO₂H) and sulfonic acid (–SO₃H).^[56,57] Cysteine is very susceptible to oxidative enzymatic reactions owing to the electron-rich sulfur atom in its side chain. This mechanism is well established in bacteria,^[57] although the link between psammoplin biosynthesis and bacteria has not been proven to date, there is strong evidence of the presence of metabolite producing microbes (Poribacteria) living in association with Verongida sponges such as *Pseudoceratina purpurea*^[58,59] which produces psammoplins.^[16,47–50]

Compounds **1–6**, **9**, and **10** were evaluated for their antiparasitic activity against *T. cruzi* Tulahuen C4, and *P. falciparum* 3D7 strains. Bisaprasin (**10**), a biphenylic dimer of psammoplin A, showed moderate activity with IC₅₀ at 19 and 29 μM, respectively, while psammoplin A (**1**) showed activity at 30 and 60 μM for the two respective parasites. Besides, psammoplin D (**4**) exhibited a lower level of activity in the two assays, but the rest of the compounds did not show any activity. All compound activities are shown in Table 2, including the results for the two standard compounds benznidazole and chloroquine (Figures S61–S62). The observed activities could be classified as low to moderate when compared to the two standard compounds.



Scheme 1. The proposed biosynthetic hypotheses of compounds **5**, **6** and **7**. ROS (reactive oxygen species), RNS (reactive nitrogen species).

Table 2. In vitro biological activity of antiparasitic assays for compounds **1–10**.

Compounds	IC ₅₀ (μM)	
	<i>T. cruzi</i> C2C4 strain	<i>P. falciparum</i> 3D7
1	30 ± 2	60 ± 2
2	> 35	> 70
3	> 66	> 131
4	43 ± 2	67 ± 3
5	> 33	> 66
6	> 32	> 64
7	> 45	> 91
8	NT	NT
9	> 57	> 115
10	19 ± 5	29 ± 6
Benznidazole ^[a]	2.6 ± 0.5	NA
Chloroquine ^[b]	NA	0.017 ± 0.002

^[a] Benznidazole as standard for *T. cruzi* C2C4 strain. ^[b] Chloroquine as standard for *P. falciparum* 3D7 strain. NT and NA represent 'not tested' and 'not applicable', respectively.

structurally characterised where two of the compounds **5** and **7** have now been isolated for the first time from the marine sponge, *Aplysinnella rhax*. These three compounds present a new finding that contributes further in widening the chemical space of this family of interesting bioactive molecules. Additionally, this study has identified bromotyrosine compounds as potential molecular architectural 'signboards' for new antiparasitic agents. Our results are in line with a recent study on two new bromotyrosine compounds isolated from an Australian marine sponge that showed potent activity against malarial parasites.^[60] After all, nature has continued to inspire drug discovery in this field as out of the 15 compounds used against parasites between 1981–2014, 9 have their origins in natural products.^[61]

Experimental Section

General

Conclusions

In conclusion, three bromotyrosine derivatives structurally related to the psammaphin family have been

UV spectra were recorded on an Agilent 1200 HPLC system coupled to a photodiode array detector (DAD).

IR spectra were recorded on a PerkinElmer UATR Two, model L1600300. Both 1D and 2D NMR data were recorded on a Bruker AVANCE III HD Prodigy TCI cryoprobe at 600 and 150 MHz for ^1H and ^{13}C , respectively. ^1H and ^{13}C chemical shift were referenced to the solvent peaks at 3.31 and 49.1 ppm (CD_3OD), respectively. HR-ESI-MS data were obtained using a ThermoScientific LTQ XL/LTQ Orbitrap Discovery coupled to a Thermo instrument Accela HPLC system, and an Agilent 6540 HR-ESI-TOF-MS coupled to an Agilent 1200 HPLC system. Fractionations were carried out on solid-phase extraction columns using C18-E (Phenomenex, 55 μm , 70 \AA , 2 g/12 mL, giga tubes). Purification was done on an Agilent 1200 semi-preparative HPLC system equipped with binary pump, photodiode array detector (DAD)22, Waters Sunfire reversed-phase column C_{18} (5 μm 10 \times 250 mm) and Agilent Zorbax C_{18} (5 μm 9.4 \times 250 mm), and a mobile phase solvent gradient between 95:5% and 20:80% ($\text{H}_2\text{O}/\text{MeOH}$).

Collection and Identification

The sponge sample was collected from the Fiji Islands in December 1997, freeze-dried and stored in 4 $^\circ\text{C}$. It was identified as *Aplysinella rhax* by Dr. John Hooper of the Queensland Centre for Biodiversity, Queensland Museum, Australia, as described in a previous publication.^[49] A voucher specimen (Voucher number: 9712SD130) is held at the Pacific Regional Herbarium at the University of the South Pacific, Suva, Fiji Islands.

Extraction and Isolation

The sponge sample was extracted with MeOH (3 \times 300 mL) followed by DCM (3 \times 200 mL), dried and partitioned following the modified Kupchan liquid-liquid partitioning technique described previously.^[44] The four fractions (WB, FM, FD and FH) were dried and weighed. The FD fraction (0.152 g) was further fractionated on a C-18 SPE using aqueous methanol (25%, 50%, 100% and 100% MeOH with TFA) as the mobile phase yielding two interesting fractions: FD-100% MeOH (80 mg) and FD50% MeOH (52.6 mg) based on ^1H -NMR profiles. The fraction FD-100% MeOH was purified on a Sunfire reversed-phase column using a gradient solvent system from 80:20 to 0:100% $\text{H}_2\text{O}/\text{MeOH}$ as mobile phase in 30 min to obtain compounds **1** (5.4 mg), **6** (1.3 mg) and **10** (5.8 mg). Using the same gradient system, FD-50% MeOH was purified to yield compounds **5** (0.5 mg), **2** (1.2 mg), **3** (3.2 mg), **4** (4.3 mg) and **8** (0.1 mg). Fractions FM and FB were

fractionated by SPE. Using the conditions described for the FD fraction with the WB-25% MeOH purified further by reversed-phase HPLC to yield compounds **7** (1.3 mg) and **9** (2.9 mg).

Psammaplin O (**5**). Yellowish oil. Yield: 0.5 mg. UV ($\text{MeOH}-\text{H}_2\text{O}$): λ_{max} (log ϵ) nm, 221 (3.72), 282 (3.14). IR (MeOH , cm^{-1}): 3312, 1660, 1538, 1494, 1330, 1144. ^1H , ^{13}C , and 2D NMR data (CD_3OD) are given in Table 1, Table S63 and Figures S22–S27. HR-ESI-MS: m/z 380.9746 $[\text{M}+\text{H}]^+$ (Figure S27), calc. for $\text{C}_{11}\text{H}_{14}\text{BrN}_2\text{O}_6\text{S}$, 380.9751, $\Delta = -0.26$ ppm. Purity of **5** was 97% based on proton NMR baseline peak analysis.

Psammaplin P (**6**). Yellowish oil. Yield: 1.3 mg. UV ($\text{MeOH}-\text{H}_2\text{O}$): λ_{max} (log ϵ) nm, 218 (3.66), 230 (3.73), 281 (3.30). IR (MeOH , cm^{-1}): 3197, 2953, 2869, 1691, 1575, 151, 1384, 1296, 1212. ^1H , ^{13}C , and 2D NMR data (CD_3OD) are given in Table 1, Table S63 and Figures S30–S35. HR-ESI-MS: m/z 494.0065 $[\text{M}+\text{H}]^+$ (Figures S28–S29), calc. for $\text{C}_{16}\text{H}_{21}\text{BrN}_3\text{O}_6\text{S}_2$, 494.0050, $\Delta = -2.8$ ppm. Purity of **6** was 95% based on ^1H -NMR baseline peak analysis.

3-Bromo-2-hydroxy-5-(methoxycarbonyl)benzoic Acid (7). Yellowish oil. Yield: 1.3 mg. UV ($\text{MeOH}-\text{H}_2\text{O}$): λ_{max} (log ϵ) nm, 227 (3.61), 258 (3.13), 312 (2.79). IR (MeOH , cm^{-1}): 3400, 2800, 1703, 1300. ^1H , ^{13}C , and 2D NMR data (CD_3OD) are given in Table 1, Table S62 and Figures S38–S41. HR-ESI-MS: m/z 274.9542 $[\text{M}+\text{H}]^+$ (Figures S36–S37), calc. for $\text{C}_9\text{H}_8\text{BrO}_5$, 274.9550, $\Delta = -1.81$ ppm. Purity of **7** was 97% based on baseline peaks analysis.

β -D-Galactosidase Transgenic Trypanosoma Cruzi in Vitro Assay

The *T. cruzi* Tulahuen C2C4 strain, expressing the β -galactosidase gene (LacZ) and L6 rat skeletal muscle cells used as host cells were cultured in RPMI-1640 supplemented with 10% iFBS, 2 mM L-glutamine, 100 U/mL penicillin, and 100 $\mu\text{g}/\text{mL}$ streptomycin at 37 $^\circ\text{C}$ and 5% CO_2 . *T. cruzi* amastigote infected L6 cell culture (2 \times 10³ infected L6 cells per well) were dispensed into 384-well assay plates already containing 5 μL of the compounds (**1–6**, **9–10**). Each compound was tested at least in duplicate using 16 points dose-response curves (1/2 serial dilution), and the starting concentrations were between 31 μM and 66 μM . The plates were incubated at 37 $^\circ\text{C}$ for 96 h. 1.5 μL of 100 μM CRPG and 0.1% NP40 diluted in PBS were subsequently added, and plates were further

incubated at 37 °C for 4 h in the dark, and then, an Envision plate reader (PerkinElmer, Waltham, MA) was used to measure the absorbance at 585 nm. The assay was normalised by using the in-plate benzimidazole at 10 µg/mL as a negative control and 0.167% DMSO as a positive growth control. The method employed in this assay was previously reported by Annang and co-workers.^[62]

Plasmodium Falciparum 3D7 Lactase Dehydrogenase in Vitro Assay

P. falciparum 3D7 strain parasites were cultured in a freshly type 0 positive (0+) human erythrocyte (Centro Regional de Transfusiones Sanguíneas-Biobanco, Granada) and the preparation for the assay was enabled by using the standard method previously described in 2016 by Pérez-Moreno and co-workers.^[63] The compounds (**1–6**, **9–10**) were tested at least in duplicate using a 16 points dose-response curve (1/2 serial dilution) with starting concentrations between 63 and 115 µM in 384-well plates. Each plate contained a parasite culture medium as a positive growth control and 100 nM of chloroquine as the negative control. The plates were incubated for 72 h after which they were frozen for 4 h and thawed at room temperature for 1 h, before LDH activity was measured. To do this, 70 µL of freshly prepared solution containing 143 mM sodium L-lactate, 143 µM APAD, 178.75 µM NBT, 1 µg/mL diaphorase, 0.7% Tween 20, and 100 mM Tris-HCl (pH 8.0) were added into the plates. Absorbance was measured at 650 nm after gently shaking the plates to ensure homogeneity and 10-min incubation at room temperature. The Envision plate reader (PerkinElmer, Waltham MA) was used to measure the absorbance in this assay.

Acknowledgements

E.O. and J.T. wish to thank Mr. Russell Gray of Marine Biodiscovery Centre, Aberdeen and Jesús Martín of Fundación Medina for NMR and mass spectrometry analysis, respectively. This work was partially supported by the European Union Erasmus+ Programme providing a mobility grant for E.O. to Granada, Spain. J.T. wishes to thank the resource owners of the district of Wainunu, Bua, Fiji Islands, for the marine sponge used in this study. M.J. wishes to thank the EU Seventh Framework Programme Project PharmaSea (grant agreement No. 312184) for financial support and F.R.

wishes to thank Fundación MEDINA, Granada, Spain, for financial support.

Author Contribution Statement

J.T. and M.J. collected the samples and designed the experiment. E.O. performed the extraction, isolation and purification of the compounds. K.S.A. assisted with the extraction process. E.O. and F.R. analysed the MS data and elucidated the structures. F.A. and G.P. performed the biological assays. E.O. and J.T. drafted the initial manuscript, which was edited and approved by all the authors.

References

- [1] World Health Organization, 'World malaria report 2019', Gen, 2019, 1–232.
- [2] A. Rassi Jr., A. Rassi, J. A. Marin-Neto, 'Chagas disease', *Lancet* **2010**, *375*, 1388–1402.
- [3] M. Leslie, 'Tropical Disease Hits the Road', *Science* **2011**, *333*, 934–934.
- [4] S. Muñoz-Saravia, A. Haberland, G. Wallukat, I. Schimke, 'Chronic Chagas' Heart Disease: A Disease on Its Way to Becoming A worldwide health problem: epidemiology, etiopathology, treatment, pathogenesis and laboratory medicine', *Heart Fail. Revs.* **2010**, *17*, 45–64.
- [5] Fact sheet about malaria. <https://www.who.int/news-room/fact-sheets/detail/malaria> (accessed Jun 22, 2020).
- [6] Chagas disease. [https://www.who.int/news-room/fact-sheets/detail/chagas-disease-\(American-trypanosomiasis\)](https://www.who.int/news-room/fact-sheets/detail/chagas-disease-(American-trypanosomiasis)) (accessed Jun 22, 2020).
- [7] World Health Organisation, 'Artemisinin resistance and artemisinin-based combination therapy efficacy', World Malaria Report, 2019, 1–6.
- [8] R. Maude, W. Pontavornpinyo, S. Saralamba, R. Aguas, S. Yeung, A. Dondorp, N. Day, N. White, L. White, 'The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia', *Malar. J.* **2009**, *8*, 1–7.
- [9] K. Wilson, K. Flanagan, M. Prakash, M. Plebanski, 'Malaria Vaccines in the Eradication Era: Current Status and Future Perspectives', *Expert Rev. Vaccines* **2019**, *18*, 133–151.
- [10] F. Annang, G. Pérez-Moreno, R. García-Hernández, C. Cordon-Obras, J. Martín, J. R. Tormo, L. Rodríguez, N. de Pedro, V. Gómez-Pérez, M. Valente, F. Reyes, O. Genilloud, F. Vicente, S. Castanys, L. M. Ruiz-Pérez, M. Navarro, F. Gamarro, D. González-Pacanoska, 'High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases', *J. Biomol. Screen* **2015**, *20*, 82–91.
- [11] T. Lang, B. Greenwood, 'The development of lapdap, an affordable new treatment for malaria', *Lancet Infect. Dis.* **2003**, *3*, 162–168.
- [12] J. Bermudez, C. Davies, A. Simonazzi, J. Pablo Real, S. Palma, 'Current drug therapy and pharmaceutical challenges for Chagas disease', *Acta Tropica* **2016**, *156*, 1–16.

- [13] M. Taylor, R. Radax, D. Steger, M. Wagner, 'Sponge-associated microorganisms: evolution, ecology, and biotechnological potential', *Microbiol. Mol. Biol. Rev.* **2007**, *71*, 295–347.
- [14] B. Carté, 'Biomedical Potential of Marine Natural Products', *BioScience* **1996**, *46*, 271–286.
- [15] D. J. Faulkner, 'Marine Natural Products: Metabolites of Marine Invertebrates', *Nat. Prod. Rep.* **1984**, *1*, 551–598.
- [16] C. Jiménez, P. Crews, 'Novel Marine Sponge Derived Amino Acids 13. Additional Psammaplin Derivatives from *Psammaplysilla purpurea*', *Tetrahedron* **1991**, *47*, 2097–2102.
- [17] A. J. Kochanowska, K. V. Rao, S. Childress, A. El-Alfy, R. R. Matsumoto, M. Kelly, G. S. Stewart, K. J. Sufka, M. T. Hamann, 'Secondary metabolites from three Florida sponges with antidepressant activity', *J. Nat. Prod.* **2008**, *71*, 186–189.
- [18] D. Newman, G. Cragg, K. Snader, 'The Influence of natural products upon drug discovery (Antiquity to late 1999)', *Nat. Prod. Rep.* **2000**, *17*, 215–234.
- [19] S. Tsukamoto, H. Kato, H. Hirota, N. Fusetani, 'Ceratinamine: An unprecedented antifouling cyanoforamamide from the marine sponge *Pseudoceratina purpurea*', *J. Org. Chem.* **1996**, *61*, 2936–2937.
- [20] V. Limna Mol, T. Raveendran, P. Parameswaran, 'Antifouling Activity Exhibited by Secondary Metabolites of the Marine Sponge, *Haliclona Exigua* (Kirkpatrick)', *Int. Biodeter. Biodegr.* **2009**, *63*, 67–72.
- [21] I. Thirionet, D. Daloze, J. Braekman, P. Willemsen, '5-Bromoverongamine, A novel antifouling tyrosine alkaloid from the sponge *Pseudoceratina* sp.', *Nat. Prod. Lett.* **1998**, *12*, 209–214.
- [22] S. Tsukamoto, H. Kato, H. Hirota, N. Fusetani, 'Ceratinamides A and B: new antifouling dibromotyrosine derivatives from the marine sponge *Pseudoceratina purpurea*', *Tetrahedron* **1996**, *52*, 8181–8186.
- [23] J. Kobayashi, K. Honma, T. Sasaki, M. Tsuda, 'Purealidins J–R, new bromotyrosine alkaloids from the Okinawan marine sponge *Psammaplysilla pura*', *Chem. Pharm. Bull.* **1995**, *43*, 403–407.
- [24] H. Lim, W. Bae, H. Lee, J. Jung, 'Anticancer activity of marine sponge *Hyrtios* sp. extract in human colorectal carcinoma RKO cells with different p53 status', *Biomed. Res. Int.* **2014**, *2014*, 1–5.
- [25] P. Shinde, Y. Lee, H. Dang, J. Hong, C. Lee, J. Jung, 'Cytotoxic bromotyrosine derivatives from a two-sponge association of *Jaspis* sp. and *Poecillastra* sp.', *Bioorg. Med. Chem. Lett.* **2008**, *18*, 6414–6418.
- [26] A. Acosta, A. Rodríguez, '11-Oxo-aerothionin: a cytotoxic antitumor bromotyrosine-derived alkaloid from the Caribbean marine sponge *Aplysina lacunosa*', *J. Nat. Prod.* **1992**, *55*, 1007–1012.
- [27] G. Tarazona, G. Santamaría, P. Cruz, R. Fernández, M. Pérez, J. Martínez-Leal, J. Rodríguez, C. Jiménez, C. Cuevas, 'Cytotoxic anomoian B and aplyzanzine B, new bromotyrosine alkaloids from Indonesian sponges', *ACS Omega* **2017**, *2*, 3494–3501.
- [28] N. Takada, R. Watanabe, K. Suenaga, K. Yamada, K. Ueda, M. Kita, D. Uemura, A. Zamamistatin, 'Significant antibacterial bromotyrosine derivative, from the Okinawan sponge *Pseudoceratina purpurea*', *Tetrahedron Lett.* **2001**, *42*, 5265–5267.
- [29] S. Tilvi, C. Rodrigues, C. Naik, P. Parameswaran, S. Wahidhulla, 'New bromotyrosine alkaloids from the marine sponge *Psammaplysilla purpurea*', *Tetrahedron* **2004**, *60*, 10207–10215.
- [30] S. Yin, R. Davis, T. Shelper, M. Sykes, V. Avery, M. Eloffson, C. Sundin, R. Quinn, 'Pseudoceramines A–D, New Antibacterial Bromotyrosine Alkaloids from the Marine Sponge *Pseudoceratina* sp.', *Org. Biomol. Chem.* **2011**, *9*, 6755–6760.
- [31] M. P. Gotsbacher, Karuso, 'New Antimicrobial bromotyrosine analogues from the sponge *Pseudoceratina purpurea* and its predator *Tylodina corticalis*', *Mar. Drugs* **2015**, *13*, 1389–1409.
- [32] J. Jang, R. van Soest, N. Fusetani, S. Matsunaga, 'Pseudoceratins A and B, antifungal bicyclic bromotyrosine-derived metabolites from the marine sponge *Pseudoceratina purpurea*', *J. Org. Chem.* **2007**, *72*, 1211–1217.
- [33] Y. Kon, T. Kubota, A. Shibasaki, T. Gono, J. Kobayashi, 'Ceratinadins A–C, new bromotyrosine alkaloids from an Okinawan marine sponge *Pseudoceratina* sp.', *Bioorg. Med. Chem. Lett.* **2010**, *20*, 4569–4572.
- [34] D. Kim, I. Lee, J. Jung, S. Yang, 'Psammaplin A, a natural bromotyrosine derivative from a sponge, possesses the antibacterial activity against methicillin-resistant staphylococcus aureus and the DNA gyrase-inhibitory activity', *Arch. Pharm. Res.* **1999**, *22*, 25–29.
- [35] B. Gorshkov, I. Gorshkova, T. Makarieva, V. Stonik, 'Inhibiting Effect of Cytotoxic Bromine-Containing Compounds from Sponges (Aplysinidae) on Na⁺-K⁺-ATPase Activity', *Toxicol.* **1982**, *20*, 1092–1094.
- [36] K. Hirano, T. Kubota, M. Tsuda, K. Watanabe, J. Fromont, J. Kobayashi, 'Ma'edamines A and B, cytotoxic bromotyrosine alkaloids with a unique 2(1H)-pyrazinone ring from sponge *Suberea* sp.', *Tetrahedron* **2000**, *56*, 8107–8110.
- [37] S. Shen, D. Liu, C. Wei, P. Proksch, W. Lin, 'Purpurines A–J, halogenated alkaloids from the sponge *Iotrochota purpurea* with antibiotic activity and regulation of tyrosine kinases', *Bioorg. Med. Chem. Lett.* **2012**, *20*, 6924–6928.
- [38] E. Fattorusso, L. Minale, G. Sodano, 'Aeropylsinin-1, an antibacterial bromo-compound from the sponge *Verongia aerophoba*', *J. Chem. Soc., Perkin 1* **1972**, 16–18.
- [39] M. Gutiérrez, T. Capson, H. Guzmán, J. González, E. Ortega-Barría, E. Quiñoá, R. Riguera, 'Antiprotozoal activity against *Plasmodium falciparum* and *Trypanosoma cruzi* of aeropylsinin-1 isolated from the new sponge *Aplysina chiriquirensis*', *Pharm. Biol.* **2005**, *43*, 762–765.
- [40] X. Yang, R. Davis, M. Buchanan, S. Duffy, V. Avery, D. Camp, R. Quinn, 'Antimalarial bromotyrosine derivatives from the Australian marine sponge *hyattella* sp.', *J. Nat. Prod.* **2010**, *73*, 985–987.
- [41] M. Xu, K. Andrews, G. Birrell, T. Tran, D. Camp, R. Davis, R. Quinn, 'Psammaplysin H, a new antimalarial bromotyrosine alkaloid from a marine sponge of the genus *Pseudoceratina*', *Bioorg. Med. Chem. Lett.* **2011**, *21*, 846–848.
- [42] E. Galeano, O. Thomas, S. Robledo, D. Munoz, A. Martinez, 'Antiparasitic bromotyrosine derivatives from the marine sponge *Verongula Rigida*', *Mar. Drugs* **2011**, *9*, 1902–1913.
- [43] S. Kupchan, K. Stevens, E. Rohlfing, B. Sickles, A. Sneden, R. Miller, R. Bryan, 'Tumor inhibitors. 126. New cytotoxic neolignans from *Aniba megaphylla* Mez.', *J. Org. Chem.* **1978**, *43*, 586–590.

- [44] J. Tabudravu, M. Jaspars, 'Stelliferin riboside, A triterpene monosaccharide Isolated from the Fijian sponge *Geodia globostellifera*', *J. Nat. Prod.* **2001**, *64*, 813–815.
- [45] J. Tabudravu, M. Jaspars, 'Puralidin S and purpuramine J, bromotyrosine alkaloids from the Fijian marine sponge *Druinella* sp.', *J. Nat. Prod.* **2002**, *65*, 1798–1801.
- [46] L. Arabshahi, F. Schmitz, 'Brominated tyrosine metabolites from an unidentified sponge', *J. Org. Chem.* **1987**, *52*, 3584–3586.
- [47] A. Rodriguez, R. Akee, P. Scheuer, 'Two bromotyrosine-cysteine derived metabolites from a sponge', *Tetrahedron Lett.* **1987**, *28*, 4989–4992.
- [48] Y. Park, Y. Liu, J. Hong, C. O. Lee, H. Cho, D. Kim, K. S. Im, J. H. Jung, 'New bromotyrosine derivatives from an association of two sponges, *Jaspis wondoensis* and *Poecillastra wondoensis*', *J. Nat. Prod.* **2003**, *66*, 1495–1498.
- [49] J. Tabudravu, V. Eijsink, G. Gooday, M. Jaspars, D. Komander, M. Legg, B. Synstad, D. van Aalten, 'Psammaplin A, a chitinase inhibitor isolated from the Fijian marine sponge *Aplysinella rhax*', *Bioorg. Med. Chem.* **2002**, *10*, 1123–1128.
- [50] I. Piña, J. Gautschi, G. Wang, G. M. Sanders, F. Schmitz, D. France, S. Cornell-Kennon, L. Sambucetti, S. Remiszewski, L. Perez, K. Bair, P. Crews, 'Psammaplins from the sponge *Pseudoceratina purpurea*: Inhibition of both histone deacetylase and DNA methyltransferase', *J. Org. Chem.* **2003**, *68*, 3866–3873.
- [51] M. Liu, P. E. Hansen, X. Lin, 'Bromophenols in marine algae and their bioactivities', *Mar. Drugs* **2011**, *9*, 1273–1292.
- [52] S. Graham, L. Lambert, G. Pierens, J. Hooper, M. Garson, 'Psammaplin metabolites new and old: an NMR study involving chiral sulfur chemistry', *Aust. J. Chem.* **2010**, *63*, 867–872.
- [53] S. Tian, N. Kishimoto, K. Ohno, 'Penning ionisation of 1-bromoadamantane and bromocyclohexane by collision with He*(23S) metastable atoms: Spin-orbit coupling effect and anisotropic interaction around bromine atom', *J. Electron Spectrosc. Relat. Phenom.* **2002**, *125*, 205–219.
- [54] S. Massil, G. Shi, I. Klotz, 'Electrostatic effects in acylation of hemoglobin by aspirins', *J. Pharm. Sci.* **1984**, *73*, 1851–1853.
- [55] G. M. Bilcer, J. C. Lilly, M. Swanson, Lisa, 'Compounds containing fused rings which inhibit beta-secretase activity and methods of use thereof', *Int. Res. Rep.* **2011**, *21*, 1–165.
- [56] V. Loi, M. Rossius, H. Antelmann, 'Redox regulation by reversible protein S-thiolation in bacteria', *Front. Microbiol.* **2015**, *6*, 1–22.
- [57] B. Ezraty, A. Gennaris, F. Barras, J. Collet, 'Oxidative stress, protein damage and repair in bacteria', *Nat. Rev. Microbiol.* **2017**, *15*, 385–396.
- [58] T. Thomas, D. Kavlekar, P. LokaBharathi, 'Marine drugs from sponge-microbe association – A Review', *Mar. Drugs* **2010**, *8*, 1417–1468.
- [59] F. Lafi, J. Fuerst, L. Fieseler, C. Engels, W. Goh, U. Hentschel, 'Widespread distribution of Poribacteria in Demospongiae', *Appl. Environ. Microbiol.* **2009**, *75*, 5695–5699.
- [60] X. Yang, R. Davis, M. Buchanan, S. Duffy, V. Avery, D. Camp, R. Quinn, 'Antimalarial bromotyrosine derivatives from the Australian marine sponge *hyattella* sp.', *J. Nat. Prod.* **2010**, *73*, 985–987.
- [61] D. Newman, G. Cragg, 'Natural products as sources of new drugs from 1981 To 2014', *J. Nat. Prod.* **2016**, *79*, 629–661.
- [62] F. Annang, G. Pérez-Moreno, R. García-Hernández, C. Cordon-Obras, J. Martín, J. Tormo, L. Rodríguez, N. de Pedro, V. Gómez-Pérez, M. Valente, F. Reyes, O. Genilloud, F. Vicente, S. Castanys, L. Ruiz-Pérez, M. Navarro, F. Gamarro, D. González-Pacanowska, 'High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases', *J. Biomol. Screen* **2015**, *20*, 82–91.
- [63] G. Pérez-Moreno, J. Cantizani, P. Sánchez-Carrasco, L. Ruiz-Pérez, J. Martín, N. el Aouad, I. Pérez-Victoria, J. Tormo, V. González-Menendez, I. González, N. de Pedro, F. Reyes, O. Genilloud, F. Vicente, D. González-Pacanowska, 'Discovery of new compounds active against *Plasmodium falciparum* by high throughput screening of microbial natural products', *PLoS One* **2016**, *11*, 1–16.

Received May 1, 2020
Accepted July 22, 2020